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LETTER
Undue regulatory control on phenobarbital
—an important yet overlooked reason for
the epilepsy treatment gap
Epilepsy is a major chronic noncommunicable neuro-
logic disorder. Although a simple, safe, efficacious, and
low-cost treatment has been available for nearly
100 years, the treatment gap remains disturbingly high in
many low- and middle-income countries (LMICs).1 Treat-
ment gap is generally defined as a “difference between the
number of people with active epilepsy and the number
being appropriately treated.” There are many reasons for
this treatment gap; one important reason is an overly
restrictive regulation on barbiturates such as phenobarbital
(PB). These restrictive regulations deserve a wider and
open discussion, even though epileptologists and others
are intensely engaged on reducing the epilepsy treatment
gap. With this article, we provide our viewpoint with an
aim of raising an extremely important issue: undue regula-
tory restriction on phenobarbital, an essential lifesaving
antiepileptic drug (AED).
TEXT AND EVIDENCE
Essential drug status versus controlled substance status
In many LMICs, PB is the first-line AED. This is
because of its satisfactory efficacy, broad coverage for
multiple seizure types, convenient use, low cost, and good
tolerability. Countries where large-scale primary-care epi-
lepsy treatment programs are ongoing have shown not only
clinical improvements with PB, but also lower costs and
long-term benefits for the patients.2 Although PB is an
“essential” medicine on most essential drugs lists in
LMICs, it is also listed with other barbiturates as a “con-
trolled substance.” There is not any particular rationale or
specific reason that PB has been listed as a scheduled sub-
stance other than that it is a barbiturate and therefore has a
potential to be a drug of abuse.3 In China, where large
demonstration project and national epilepsy programs
have taken place, there have been no major negative
impact on cognitive function of people with convulsive
seizures treated with PB, but instead cognitive gains have
been observed as a result of PB treatment.4 Treatment
guidelines call for controlled substances such as AEDs to
be readily available, but this has not been the case in many
LMICs.5,6 As noted by the World Health Organization
(WHO), international drug-control conventions provide
the basic framework for national drug-control legislation
(Box 1).
Restrictions function at two levels
Regulatory restrictions may function at two levels—
international and national. First, restrictions posed by
international agencies may restrict a country’s ability to
meet its own drug requirements. For instance in Lao
People’s Democratic Republic, the International Narcot-
ics Control Board (INCB) delivers an annual quota of
25 kg of raw PB to Laos’s Food and Drug Department.
This allows the production of 245,000 PB tablets per
year, equivalent to 671 annual adult treatments.5 But
Laos has >40,000 people with epilepsy (PWE) who need
access to treatment, so the policy is contrary to what is
required and what INCB declared in its recent annual
report: “One of the fundamental objectives of the inter-
national drug control treaties is to ensure the availability
of narcotic drugs and psychotropic substances for medi-
cal and scientific purposes and to promote access to and
rational use of narcotic drugs and psychotropic sub-
stances.”6 Second, countries may introduce additional
Box 1
Relevant laws and principles
Single Convention on Narcotic Drugs, Preamble,
paragraph 2: “Recognizing that the medical use of
narcotic drugs continues to be indispensable for the relief
of pain and suffering and that adequate provision must be
made to ensure the availability of narcotic drugs for such
purposes.”18
Convention on Psychotropic Substances, Preamble,
paragraph 5: “Recognizing that the use of psychotropic
substances for medical and scientific purposes is
indispensable and that their availability for such purposes
should not be unduly restricted.”6
United Nations Office on Drugs and Crime: “Ensuring
availability of controlled medications for the relief of pain
and preventing diversion and abuse - Striking the right
balance to achieve the optimal public health outcome.”18
Constitution of Cambodia (article 72): “Right to health,
and obligation on the State to provide high-level medical
treatment and to give full consideration to disease
prevention.”19
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drug regulations that go beyond the international conven-
tions, rarely assessing their effect on the accessibility of
essential drugs. In Zambia, the Zambian Pharmacy
regulatory agency newly enforced regulatory require-
ments to facilitate proper management of scheduled
medications in line with the recommendations of WHO
Expert Committee on Drug Dependence. However, these
unintended actions have in fact led to a decreased avail-
ability of PB, with the consequence that nearly 50% of
pharmacies do not have a stock of PB, and pediatric
syrups are completely unavailable, therefore, risking the
lives of children.7
What reality says
WHO has also specified that national drug control pol-
icies should recognize that controlled medicines are also
absolutely necessary for medical and scientific purposes.6
We conducted an informal survey to determine the regu-
lation, availability, and utilization of PB in different
countries. Twenty-five neurologists from 20 LMICs in
Asia (n = 3), Africa (n = 12), and Latin America
(N = 5) reported PB to be the first-line AED in 60%
(n = 12) of their countries (unpublished data, Pierre-
Marie Preux, 2013). Fifty-five percent of countries
(n = 11) rely solely on imports to meet their PB needs,
with 10% (n = 2) relying on both in-country production
and importation of PB. In 40% of countries (n = 8), tight
regulations exist that restrict the availability of PB. In
12% of countries (n = 3, Burkina Faso, Burundi, and
Brazil), specific border restrictions prohibit the importa-
tion of PB. In Burundi, PB was not allowed inside the
country from the Border Post (perssonal data, Pierre-
Marie Preux, 2013) leading to a 3-month interruption in
the supply to that country. PB is on the essential drug list
in Pakistan, but its listing as a narcotic makes PB
unavailable in the market, although it is often available
illicitly to those with substance abuse (personal data,
Hasan Aziz, 2014).
Training helps
WHO has introduced the Mental Health Gap Action
Programme (mhGAP) intervention Guide (mhGAP-IG),
which includes management of epilepsy, substance abuse,
and other disorders in nonspecialist health settings.8 By
training health care providers with such a tool, govern-
ments can reduce the risk that controlled substances may
be handled inappropriately without ignoring the need to
give access to these substances for therapeutic use. In Tan-
zania, treating epilepsy has been incorporated into the
basic tasks and activities of mental health nurses with
training in the appropriate use of “controlled substances.”9
Therefore, appropriate training can be a useful mitigating
tool to facilitate safer use of scheduled substances such as
PB.
Role of pharmaceutical companies
By increasing production of PB, manufacturers may
play an important role in increasing PB access and
reducing the epilepsy treatment gap. However, it is likely
that too many regulatory controls discourage pharmaceu-
tical companies from engaging in active production of
PB; as a result possibly affecting treatment coverage.
Moreover, some countries have shown to have with-
drawn PB with little notice.10 Ghana Health Ministry has
recognized the importance of public-private partnership
with pharmaceutical manufacturers in order to increase
access to PB.11
Potential cons of PB
Although PB is often viewed more as a drug of abuse
than as a medication, PB in fact has low abuse potential.12
Abusing PB, for instance for suicide, should also be looked
individually for each country, since there may be excep-
tions, such as Cambodia.13 In addition, almost all black
market barbiturates are diverted from legitimate medical
practice/sources.14 Therefore, use of security barcodes on
the packets of AEDs (and other controlled substances) and
specific registration numbers may be of help in reducing
diversion to illicit market to some extent. This step could
be feasible, since according to the WHO, just five coun-
tries—the U.S.A., Japan, Germany, France, and United
Kingdom account for two-thirds of the value of all medi-
cines produced worldwide.15 Moreover, in large studies
conducted in LMICs, PB is not found to have a major cog-
nitive neurotoxicity and in fact renders some cognitive
gains to the patients treated with PB.4 Despite its numerous
advantages and wider use, PB is not the ideal AED, but is
just like any other AED. Coadministration of this or other
enzyme-inducing AEDs and antiretroviral drugs can possi-
bly result in virologic failure, breakthrough seizures, or
AED or antiviral toxicity.16 The teratogenic risk of PB in
pregnancy may be higher than that of some other AEDs.3
But for the moment, LMICs are often presented with either
having a treatment with PB or having no treatment at all.17
Therefore, any barriers to its use in countries needing it
should be reduced.
Finally, to conclude, the millennium development goal
8E (see Key Messages) requires that the access to essential
medicines, including for people with epilepsy, should be
ensured. Medicines that are life-saving, essential, and,
more so, effective and safe, cannot be withheld from the
health care systems purely on the grounds that they are
listed in the international drug conventions. We urge
international agencies such as WHO and the International
League Against Epilepsy (ILAE) to initiate a wider and
open debate on this important subject.
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Key Messages
1 PB is an essential first-line and life-saving drug for
many PWEs in most LMICs.
2 Although it is not an ideal AED, the cost–benefit ratio
supports its widespread use for epilepsy in LMICs.
3 Each country should self-help for determining nega-
tive consequences (e.g., suicidal tendency) attributed
to PB exclusively, instead of adopting a generalized
opinion, since exceptions to this have been shown to
exist in LMICs.
4 Phenobarbital should not be withheld from the
health care systems just because it is listed in the
international drug conventions. Such an action will
prevent the achievement of the millennium develop-
ment goal 8E.
Millennium Development Goal 8E: In cooperation
with pharmaceutical companies, provide access to
affordable essential medicines in developing coun-
tries.
LMICs, low- and middle-income countries; PB,
phenobarbital; PWE, people with epilepsy.
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Recruitment of patients with both epilepsy
and intellectual disability
To the Editors:
With great interest we took notice of the recent paper
entitled “Genetic testing preferences in families contain-
ing multiple individuals with epilepsy” by Okeke et al.1
In this study on 143 individuals with epilepsy and 165
relatives without epilepsy they found that interest in
genetic testing in families with epilepsy may be high,
especially when testing has implications for improving
clinical care.
We would like to add additional data that show that
the other way around, a low interest when there is no
benefit, is also true, at least for patients with both epi-
lepsy and intellectual disability (ID). Our observation is
based on two different cross-sectional studies that
attempted to include the complete population of our
institutionalized patients with both epilepsy and ID. The
first study was an anonymous study concerning genetic
risk factor for epilepsy. The blood samples for DNA
analysis were acquired together with the annual routine
laboratory examinations. There was no benefit to the
patient. In this study, 266 subjects were asked to partici-
pate: 79 (30%) were included, 66 (25%) refused and 121
(45%) did not respond. The second study focused on the
diagnosis and treatment of osteoporosis. This was an
invasive study that included measurements of bone den-
sity.2 Treatment was offered when osteoporosis was
diagnosed. Of the 260 subjects eligible for the study, 205
subjects (79%) were included, 32 (12%) refused, and 23
(9%) did not respond. In both studies, the patients and
their families were informed in a similar manner by the
same staff.
In line with the observation of Okeke et al., we found a
relatively high inclusion rate in the study that did have
implications for clinical care. The low interest in our study
on genetic risk factors could potentially also be explained
by the fact that, although it was an anonymous study, there
still was the fear that the results would have consequences
for other family members. This issue was addressed by
Dlugos et al.,3 who looked at the inclusion rate of children
in a genetic susceptibility study on the common forms of
epilepsy. In their study, they found that patients refused
because of the fear of phlebotomy and not because of the
fear of genetic testing. An interesting aspect concerning
the inclusion of patients with both epilepsy and ID is the
role of the legal guardian. To give consent for a person you
care for might, especially when there is no benefit to be
expected, be even more difficult than when it would be for
yourself.
We conclude that in genetic studies on patients with
both epilepsy and ID, the absence of direct clinical rele-
vance, will negatively influence the inclusion rate for that
study. Genetic studies are important because they could
improve knowledge about underlying mutations, which
may provide insight into the natural course, effective an-
tiepileptic treatments, recurrence risk, or comorbidity and
enables specific anticipation on these topics. Therefore, it
is important to explain explicitly the added value of a
genetic diagnosis to improve participating and to move
forward.
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ANNOUNCEMENTS
31st International Epilepsy Congress
5–9 September, 2015; Istanbul, Turkey.
Please see the congress website: www.epilepsyistanbul
2015.org.
Regional Congresses
12th European Congress on Epileptology
11–15 September, 2016; The Prague Congress Centre,
Czech Republic.
Website: www.epilepsyprague2016.org.
Upcoming Chapter Congresses
The Annual Emirates league epilepsy
meeting
22–23May, 2015; Dubai, UAE.
5th SEIN Course on Clinical Epileptology
8–19 June, 2015; Stichting Epilepsie Instellingen
Nederland (SEIN), the Netherlands.
The course objective is to improve diagnosis and treat-
ment of epilepsy in the student’s own clinical setting by
offering young doctors the opportunity to follow a short,
yet comprehensive and practically oriented training in
clinical epileptology in both lectures and interactive
workshops/discussion sessions.
Application Deadline: 24 October, 2014.
Information: cmorton@sein.nl
Brazilian Epilepsy Congress
9–11 June, 2016; Recife, Brazil.
Other Congresses
2nd International Residential Course on
Drug Resistant Epilepsies in Tagliacozzo
3–9May, 2015, Tagliacozzo, Italy.
Topics: semiologic characteristics of different types of
epileptic seizures, utilization of Video-EEG, notions of
antiepileptic drug pharmacodynamics and kinetics,
alternative treatments, role of epilepsy surgery, and
more.
Announcement
Antiepileptic Drug Trials XIII
Conference
13–15May, 2015; May 13–15, 2015.
Aventura (North Miami Beach), Florida.
Website: http://www.epilepsy.com/accelerating-new-ther-
apies/antiepileptic-drug-trials-xiii-conference-may-
2015
XXIV European Stroke Conference (ESC)
2015
13–15May, 2015; Vienna, Austria.
Website: http://www.eurostroke.org/default.html
5th SEIN Course on Clinical
Epileptology
8–19 June, 2015; Stichting Epilepsie Instellingen
Nederland (SEIN), the Netherlands.
The course objective is to improve diagnosis and treat-
ment of epilepsy in the student’s own clinical setting by
offering young doctors the opportunity to follow a short,
yet comprehensive and practically oriented training in
clinical epileptology in both lectures and interactive
workshops/discussion sessions.
Application Deadline: 24 October, 2014. Information:
cmorton@sein.nl.
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1st Congress of the European Academy of
Neurology (EAN)
20–23 June, 2015; Berlin, Germany.
Congress website: http://www.eaneurology.org/ber-
lin2015/
GLUT1-Deficiency Annual
Conference
6–8 July, 2015; Orlando, Florida.
Information: www.g1dfoundation.org
International advanced course on Seizures
and Epilepsies in Childhood:Management,
co-morbidities, and adaptation of
guidelines
19–31 July 2015; ISNV, Venice International Univer-
sity, San Servolo, Venice, Italy.
Course directors: Jo Wilmshurst (South Africa) and
Marilena Vecchi (Italy).
Announcement
For more information: epilepsysummercourse@univiu.
org.
3rd International Summer School for
Neuropathology and Epilepsy Surgery
(INES 2015)
26–30 July, 2015; State University of Campinas –
UNICAMP, Brazil.
Information | Past INES meetings | Contact: blue-
mcke@uk-erlangen.de
9th Baltic Sea Summer School on Epilepsy
(BSSSE 9)
2–7 August, 2015; Sigulda, Latvia.
Improve your level in epileptology by studying in a
setting of young international peers with a group of
dedicated and experienced tutors!
Information | Past BSSSE Schools
Contact: petra.novotny@wolfstiftung.org | www.epilep-
siestiftung-wolf.de
Epilepsy Mechanisms, Models, Prediction
and Control: 7th International
Workshop on Seizure Prediction
(IWSP7)
3–6 August, 2015; University of Melbourne, Australia.
Program: http://www.ilae.org/Commission/CAOA/doc-
uments/IWSP7_Program-2014.pdf
XIIIWorkshop on Neurobiology of
Epilepsy (WONOEP) 2015
31 August – 4 September, 2015.
Heybeliada Island, Turkey.
Announcement: http://www.ilae.org/Visitors/Congress/
congressinfo/WONOEP_announce15.pdf
About WONOEP: http://www.ilae.org/Visitors/Con-
gress/Ed-WONOEP.cfm
For more information, email: decurtis@istituto-besta.it.
2nd International Epilepsy
Symposium
4–5 September, 2015; Bielefeld-Bethel, Germany.
Main topics: Epilepsy, cognition, autoimmunity and
surgical therapy.
Organizers: Epilepsy Centers Bethel and Berlin-Bran-
denburg.
Information: bbs2015@mara.de.
International Symposium on Benign
Infantile Seizures (ISBIS)
25–26 September, 2015; Chiyoda-ku, Tokyo, Japan.
Information | Website
15th European Congress on Clinical
Neurophysiology
30 September–4 October, 2015; Brno, Czech Republic.
Congress website: http://www.eccn2015.eu/
6th Eilat International Educational Course
on the Pharmacological Treatment of
Epilepsy (6thEilat Edu)
12–16 October, 2015; Jerusalem, Israel.
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Presented by ILAE-CEA, Israeli League Against
Epilepsy, and CURE.
Flyer | Program
Congress website: www.eilatedu2015.com
XXIIWorld Congress of Neurology (WCN
2015)
31 October–5 November, 2015; Santiago, Chile.
Website: http://www.wcn-neurology.com/
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